Clinical Trial Update: Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update examining nivolumab in combination with BMS986205 for stage II-IV squamous cell cancers of the head and neck, including …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Laryngeal Squamous Cell Carcinoma
• Lip Squamous Cell Carcinoma
• Oral Cavity Squamous Cell Carcinoma
• Pharyngeal Squamous Cell Carcinoma
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• BMS986205 (BMS-986205)
• nivolumab (nivolumab)

Snippet

Sponsor: Thomas Jefferson University | Conditions: Lip, Oral Cavity Squamous Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING